Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Don B. Axworthy"'
Autor:
Don B. Axworthy, Anna Dilhas, Pat Zanzonico, Sarah M. Cheal, Steven M. Larson, Ouathek Ouerfelli, Geralda Torchon, Guangbin Yang, Jun Pu, Barney Yoo, Blesida Punzalan, Sarah Boughdad
Publikováno v:
Molecular Pharmaceutics. 11:400-416
A series of N-acetylgalactosamine-dendrons (NAG-dendrons) and dextrans bearing biotin moieties were compared for their ability to complex with and sequester circulating bispecific anti-tumor antibody (scFv4) streptavidin (SA) fusion protein (scFv4-SA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a522dea18794ceca97fcfdb410eaec83
https://doi.org/10.1021/mp4003128
https://doi.org/10.1021/mp4003128
Autor:
Diane Stone, Yukang Lin, Don B. Axworthy, Shani M. Wilbur, Ajay K. Gopal, Anastasia Pantelias, D. Scott Wilbur, Laura Saganic, Donald K. Hamlin, Oliver W. Press, John M. Pagel, Nathan Hedin
Publikováno v:
Blood. 109:4980-4987
Pretargeted radioimmunotherapy (PRIT) using streptavidin (SA)–conjugated antibodies (Abs), followed by clearing agent and radiolabeled biotin is a promising method that can increase the effectiveness of RIT, while decreasing the toxicities associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e71f8ea9060f41099b1329071d604349
https://doi.org/10.1182/blood-2006-11-056895
https://doi.org/10.1182/blood-2006-11-056895
Autor:
Andres, Forero-Torres, Sui, Shen, Hazel, Breitz, Robert B, Sims, Don B, Axworthy, M B, Khazaeli, Kuang-Ho, Chen, Ivor, Percent, Stephen, Besh, Albert F, LoBuglio, Ruby F, Meredith
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 20:379-390
Pretargeted radioimmunotherapy (RIT) increases the dose of radionuclide delivered to tumor sites while limiting radiation to normal tissues. The three components in Pretarget include a streptavidin-containing targeting molecule, a synthetic clearing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8e8743b5fc0f59640afdaff8dab5f05
https://doi.org/10.1089/cbr.2005.20.379
https://doi.org/10.1089/cbr.2005.20.379
Autor:
Michael L. Goris, Hazel B. Breitz, Julie M. Vose, Jordan Hankins, Don B. Axworthy, Vincent J. Picozzi, Andres Forero, Richard G. Ghalie, Albert F. LoBuglio, Robert B. Sims, Ruby F. Meredith, Sui Shen, Paul L. Weiden, Susan J. Knox
Publikováno v:
Blood. 104:227-236
Pretargeted radioimmunotherapy (PRIT) has the potential to increase the dose of radionuclide delivered to tumors while limiting radiation to normal tissues. The purpose of this phase 1 trial is to assess safety of this multistep approach using a nove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f997f68761b5d86c10a507305e90fc11
https://doi.org/10.1182/blood-2003-09-3284
https://doi.org/10.1182/blood-2003-09-3284
Autor:
Timothy Johnson, Louis J. Theodore, D. Scott Wilbur, Robert W. Mallett, Krishnan Subbiah, Eric K Yau, Oliver W. Press, Don B. Axworthy, Damon L. Meyer, Don K. Hamlin, Melissa C. Corcoran
Publikováno v:
Blood. 98:2535-2543
Radioimmunotherapy with anti-CD20 monoclonal antibodies is a promising new treatment approach for patients with relapsed B-cell lymphomas. However, the majority of patients treated with conventional radiolabeled anti-CD20 antibodies eventually have a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45321d0e9335e87f997826085e6aca27
https://doi.org/10.1182/blood.v98.8.2535
https://doi.org/10.1182/blood.v98.8.2535
Autor:
Jim Simon, Silvia S. Jurisson, William H. Miller, Don B. Axworthy, Michael R. Lewis, Alan R. Ketring, Geethapriya Sivaguru, Huma Mohsin, R. Keith Frank, Jeffrey N. Bryan, Louis J. Theodore, Cathy S. Cutler, Fang Jia
Publikováno v:
Bioconjugate chemistry. 22(12)
The therapeutic efficacies of radiolabeled biotin, pretargeted by monoclonal antibody (mAb)-streptavidin fusion protein CC49 scFvSA, were compared to those of radiolabeled mAb CC49, using the three radiolanthanides in an animal model of human colon c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c7d1dd95ba7148dc353e3f048490ec
https://pubmed.ncbi.nlm.nih.gov/22053899
https://pubmed.ncbi.nlm.nih.gov/22053899
Autor:
Don K. Hamlin, Don B. Axworthy, Damon L. Meyer, Oliver W. Press, Kevin J. Hamblett, Patrick S. Stayton, D. Scott Wilbur
Publikováno v:
Bioconjugate chemistry. 16(1)
One pretargeting approach to cancer radioimmunotherapy utilizes an antibody-streptavidin conjugate that is first localized to the tumor. A "clearing agent" is then administered to remove the excess bioconjugate from blood, followed by injection of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90b57bb1cbcf75805742c9f0888f624a
https://pubmed.ncbi.nlm.nih.gov/15656584
https://pubmed.ncbi.nlm.nih.gov/15656584
Autor:
Krishnan, Subbiah, Don K, Hamlin, John M, Pagel, D Scott, Wilbur, Damon L, Meyer, Don B, Axworthy, Robert W, Mallett, Louis J, Theodore, Pat S, Stayton, Oliver W, Press
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 44(3)
Pretargeted radioimmunotherapy (RIT) using streptavidin (sAv)-conjugated antibodies before radiolabeled-biotin is a promising approach to improve absorbed dose ratios and achieve high durable remission rates with diminished systemic toxicity. This st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4eea038398b0af78aa0bd61ee9f3fdcf
https://pubmed.ncbi.nlm.nih.gov/12621012
https://pubmed.ncbi.nlm.nih.gov/12621012
Autor:
Oliver W. Press, John M. Reno, Don B. Axworthy, Darrell R. Fisher, J. Kyle Bryan, Hazel B. Breitz, Sally Gaffigan, Janet W. Appelbaum, Paul L. Weiden, Diane Stone
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 15(1)
Pretargeted radioimmunotherapy (PRIT) was investigated in patients with non-Hodgkin's lymphoma (NHL). The PRIT approach used in this study is a multi-step delivery system in which an antibody is used to target streptavidin to a tumor associated antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7e82a91ffffa424230410d647733c32
https://pubmed.ncbi.nlm.nih.gov/10740647
https://pubmed.ncbi.nlm.nih.gov/10740647
Autor:
Huma Mohsin, Fang Jia, JeffreyN. Bryan, Geethapriya Sivaguru, Cathy S. Cutler, Alan R. Ketring, WilliamH. Miller, Jim Simón, R. Keith Frank, Louis J. Theodore, Don B. Axworthy, Silvia S. Jurisson, Michael R. Lewis
Publikováno v:
Bioconjugate Chemistry; Dec2011, Vol. 22 Issue 12, p2444-2452, 9p